Why the study?
Although BMI and WC have served as obesity metrics, VAT directly underlies obesity-related metabolic disease, prompting investigation into whether VAT better predicts metabolic syndrome, T2DM, and insulin resistance.
Is visceral adipose tissue a stronger predictor of metabolic syndrome, type 2 diabetes, and insulin resistance than BMI, percent body fat, or waist circumference in US adults?
Is visceral adipose tissue a stronger predictor of metabolic syndrome, type 2 diabetes, and insulin resistance than BMI, percent body fat, or waist circumference in US adults?
Answers are grounded in this paper and cite their sources.
Visceral adipose tissue estimation provides high classification performance for metabolic disease risk, with a suggested threshold of ≥100 cm², though it may not offer a clear advantage over simple waist circumference.
Background Body mass index (BMI) and waist circumference (WC) have served as primary metrics of obesity disease risk for the past 50+ y, but visceral adipose tissue (VAT) is the more direct etiological basis of obesity-related metabolic disease. Increasing availability of technologies for VAT estimation now makes it possible to practically apply this more precise assessment of individual risk. Objectives We hypothesized that VAT is a stronger predictor of metabolic syndrome, type 2 diabetes mellitus (T2DM), and insulin resistance [as measured by homeostasis model assessment of insulin resistance (HOMA-IR)] in United States adults than BMI, percent body fat (%BF), or WC. This hypothesis was tested using data from the National Health and Nutrition Examination Survey (NHANES). Methods Cross-sectional data from 4139 men and 4147 women, aged 18–59 y, from NHANES survey years 2011–2018, were analyzed for BMI, %BF, WC, WC/height, and VAT determined by dual-energy X-ray absorptiometry, compared with MetS disease risk outcomes classified as ≥3 markers, T2DM (glycated hemoglobin ≥6.5), insulin resistance (by HOMA-IR ≥2.0). Results Receiver operating characteristic curves and area under the curve (AUC) revealed high classification performance for VAT to MetS [AUC 0.84 ± 0.01 standard error (SE)], T2DM (AUC 0.80 ± 0.01 SE), and HOMA-IR (AUC 0.79 ± 0.01 SE). VAT risk thresholds for MetS were observed at 103 cm 2 (95% confidence interval: 0.83–0.85), slightly higher for T2DM (119 cm 2 ; 0.78–0.81), and lower for HOMA-IR (84 cm 2 ; 0.78–0.80). WC performed similarly to VAT in several of these comparisons. Conclusions These data suggest that VAT estimates may improve individual obesity risk management although this analysis did not demonstrate a clear advantage of VAT or a simple WC or WC/height. These data suggest a sex-independent threshold could be set for metabolic disease risk at approximately VAT ≥ 100 cm 2 .
No takes yet. Share an insight, caveat, or question.
Potter et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: